Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference
June 07, 2021 13:30 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that...
Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia
May 19, 2021 06:45 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it...
Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
May 06, 2021 06:45 ET
|
Reata Pharmaceuticals, Inc.
ANNOUNCES FDA ACCEPTED FOR FILING REATA’S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME IF APPROVED, BARDOXOLONE MAY BECOME THE FIRST APPROVED THERAPY FOR ALPORT...
Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences
May 03, 2021 06:45 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that...
Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021
April 28, 2021 17:00 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will...
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
April 26, 2021 16:54 ET
|
Reata Pharmaceuticals, Inc.
Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies Application Assigned a PDUFA Date of February 25,...
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors
April 15, 2021 06:45 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the...
Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences
March 29, 2021 17:34 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that...
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs
March 01, 2021 06:35 ET
|
Reata Pharmaceuticals, Inc.
ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY’S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME PROVIDES UPDATE ON FALCON STUDY OF BARDOXOLONE IN ADPKD ANNOUNCES FIRST PATIENT ENROLLED IN MERLIN TRIAL...
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome
March 01, 2021 06:30 ET
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has...